喉鳞状细胞癌MTS1/p16基因纯合子缺失的检测  

Homozygous deletions of MTS1/p16 gene in laryngeal squamous cell carcinoma

作　　者：李华伟[1] 杨强[1] 詹汉章[1] 

机构地区：[1]湖北医科大学第一附属医院耳鼻咽喉头颈外科,武汉430060

出　　处：《基础医学与临床》2001年第2期163-165,共3页Basic and Clinical Medicine

基　　金：湖北省教委科研基金! (鄂教科技 1991- 0 30 ;No.0 32 )

摘　　要：为探讨MTS1/p16基因在喉癌中纯合子缺失情况及其与喉癌生物学行为的关系 ,本研究用比较PCR技术对 5 9例喉鳞状细胞癌 (LSCC)MTS1/ p16基因纯合子缺失进行检测。剔除 3例不可比样本 ,9/ 5 6LSCC有MTS1/p16基因纯合子缺失 ,缺失率为 16 0 7%。MTS1/ p16基因纯合子缺失与LSCC病理分级无关 ;LSCC晚期 (Ⅲ～Ⅳ期 )的MTS1/ p16基因纯合子缺失率 (36 84% )明显高于早期 (Ⅰ～Ⅱ期 )肿瘤 (5 41% ) ,P <0 0 1,显示MTS1/p16基因纯合子缺失与LSCC的自然病程有关。认为MTS1/ p16基因纯合子缺失是LSCC发生发展过程中的分子机制之一 ,可能与LSCC的恶性发展有关。To study the status of homozygous deletions of MTS1/p16 gene in squamous cell carcinoma of the larynx (LSCC) and to discuss the relations of homozygous deletions to the pathological grade and clinical stage of the tumor, Fifty nine primary LSCC were examined for homozygous deletions of the MTS1/p16 gene by comparative PCR Three specimens were eliminated for being incapable of comparison with others Homozygous deletions of the MTS1/p16 gene were found in 9 of 56 tumors (16 07%) The rates of homozygous deletions of MTS1/p16 gene in well, medially, poorly differentiated tumors were 17 24%(5/29), 11 76%(2/17), and 20 00%(2/10) respectively There had no significant difference in various pathological grades of tumors Homozygous deletions rates of tumors in stagesⅠ～Ⅱand in stagesⅢ～Ⅳwere 5 41% (2/37) and 36 84%(7/19) respectively The rate of homozygous deletions in stages Ⅲ～Ⅳtumors was significantly higher than that in stagesⅠ～Ⅱ( P <0 01) Homozygous deletions of the MTS1/p16 gene were correlated well with clinical stages Our data suggested that homozygous deletions of MTS1/p16 gene might be one of the genetic events in the development of the tumor and might play a role in malignant progression of LSCC

关 键 词：喉癌 多肿瘤抑制因子-Ⅰ 基因缺失 聚合酶链反应 喉鳞状细胞癌 

分 类 号：R739.65[医药卫生—肿瘤]